KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Retained Earnings: 2015-2024

Historic Retained Earnings for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Dec 2024 value amounting to -$1.4 billion.

  • CRISPR Therapeutics AG's Retained Earnings fell 36.75% to -$1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 billion, marking a year-over-year decrease of 36.75%. This contributed to the annual value of -$1.4 billion for FY2024, which is 36.64% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Retained Earnings stood at -$1.4 billion for FY2024, which was down 36.64% from -$999.7 million recorded in FY2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Retained Earnings peaked at -$195.9 million during FY2021, and registered a low of -$1.4 billion during FY2024.
  • Over the past 3 years, CRISPR Therapeutics AG's median Retained Earnings value was -$999.7 million (recorded in 2023), while the average stood at -$1.1 billion.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Retained Earnings surged by 65.84% in 2021, and later slumped by 331.87% in 2022.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's Retained Earnings stood at -$573.6 million in 2020, then skyrocketed by 65.84% to -$195.9 million in 2021, then slumped by 331.87% to -$846.1 million in 2022, then decreased by 18.16% to -$999.7 million in 2023, then crashed by 36.64% to -$1.4 billion in 2024.